| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c24a766694d15126e9f965aaa29c836c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T428-2984 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7028
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-252
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
1985-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cd6ccac739fa6457901b4c3b49033f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c7367657f3bbae3f55fe2b8afc7f0a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dc0ebca023e9c17580c19de064cf380 |
| publicationDate |
1987-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-S62129221-A |
| titleOfInvention |
Liposome preparation containing embedded adriamycin |
| abstract |
PURPOSE:To obtain the titled drug preparation having suppressed side effect compared with conventional drug and maximized carcinostatic action, by embedding adriamycin in a liposome consisting of phosphatidylcholine, cholesterol and sulfatide at specific molar ratios. CONSTITUTION:A liposome preparation containing adriamycin embedded in a liposome having molar ratios of constituent lipids (phosphatidylcholine: cholesterol:sulfatide) of about 5:4:1. The concentration of adriamycin in blood can be increased compared with conventional preparation having the molar ratios of 7:2:1 and the requisite condition to suppress the accumulation of adriamycin in the heart can be fulfilled in a well-balanced state. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012162577-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H05194191-A |
| priorityDate |
1985-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |